Patents by Inventor GUIDO SILVESTRI

GUIDO SILVESTRI has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20140255426
    Abstract: In certain embodiments, the disclosure relates to methods of treating or preventing a viral infection comprising administering an effective amount of a Wnt pathway inhibitor optionally in combination with one or more anti-viral agents. In certain embodiments, the subject is diagnosed with a chronic viral infection such as human immunodeficiency virus (HIV).
    Type: Application
    Filed: March 10, 2014
    Publication date: September 11, 2014
    Applicants: EMORY UNIVERSITY, Children's Healthcare of Atlanta, Inc., The General Hospital Corporation
    Inventors: Guido Silvestri, Ann M. Chahroudi, Mathias Lichterfeld, Maria Jose Buzon, Raymond F. Schinazi
  • Publication number: 20090263830
    Abstract: This invention provides a non-radioactive assay to monitor and quantify the target-cell killing activities mediated by cytotoxic T lymphocytes (CTLs). This assay is predicated on the discovery that apoptosis pathway activation and, in particular, caspase activity, provides a measure of cytotoxic effector cell activity. In one embodiment, measurement of CTL-induced caspase activation in target cells is achieved through detection of the specific cleavage of fluorogenic caspase substrates. This assay reliably detects antigen-specific CTL killing of target cells, and provides a more sensitive, more informative and safer alternative to the standard 51Cr-release assay most often used to quantify CTL responses. The assay can be used to study CTL-mediated killing of primary host target cells of different cell lineages, and enables the study of antigen-specific cellular immune responses in real time at the single-cell level.
    Type: Application
    Filed: March 3, 2009
    Publication date: October 22, 2009
    Applicant: Oncoimmunin, Inc.
    Inventors: BEVERLY PACKARD, MARTIN J. BROWN, MARK FEINBERG, LUZHENG LIU, GUIDO SILVESTRI, ANN CHAHROUDI, AKIRA KOMORIYA
  • Publication number: 20030211548
    Abstract: This invention provides a non-radioactive assay to monitor and quantify the target-cell killing activities mediated by cytotoxic T lymphocytes (CTLs). This assay is predicated on the discovery that apoptosis pathway activation and, in particular, caspase activity, provides a measure of cytotoxic effector cell activity. In one embodiment, measurement of CTL-induced caspase activation in target cells is achieved through detection of the specific cleavage of fluorogenic caspase substrates. This assay reliably detects antigen-specific CTL killing of target cells, and provides a more sensitive, more informative and safer alternative to the standard 51Cr-release assay most often used to quantify CTL responses. The assay can be used to study CTL-mediated killing of primary host target cells of different cell lineages, and enables the study of antigen-specific cellular immune responses in real time at the single-cell level.
    Type: Application
    Filed: January 28, 2003
    Publication date: November 13, 2003
    Applicant: Oncolmmunin, Inc.
    Inventors: Beverly Packard, Martin J. Brown, Mark Feinberg, Luzheng Liu, Guido Silvestri, Ann Chahroudi, Akira Komoriya